Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Hot Stocks
Epam Systems CMO sells over 2,000 common shares » 16:07
05/22/20
05/22
16:07
05/22/20
16:07
EPAM

Epam Systems

$222.97 /

-1.78 (-0.79%)

In a regulatory filing,…

In a regulatory filing, Epam Systems chief marketing officer Elaina Shekhter disclosed the sale of 2,349 common shares of the company on May 20 at a price of $223.96 per share.

ShowHide Related Items >><<
EPAM Epam Systems
$222.97 /

-1.78 (-0.79%)

EPAM Epam Systems
$222.97 /

-1.78 (-0.79%)

05/22/20 Piper Sandler
Piper expands Software coverage, favors companies that drive automation
05/21/20 Piper Sandler
Epam Systems initiated with an Overweight at Piper Sandler
05/08/20 Needham
Epam Systems price target raised to $265 from $200 at Needham
05/08/20 Wells Fargo
Epam Systems downgraded at Wells Fargo following Q1 results
EPAM Epam Systems
$222.97 /

-1.78 (-0.79%)

EPAM Epam Systems
$222.97 /

-1.78 (-0.79%)

Hot Stocks
FDA approves Evofem's Phexxi gel for prevention of pregnancy » 16:07
05/22/20
05/22
16:07
05/22/20
16:07
EVFM

Evofem

$5.02 /

+0.22 (+4.58%)

Evofem announced that the…

Evofem announced that the FDA has approved Phexxi vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 - an acidic environment that is inhospitable to sperm. The company expects to launch Phexxi in early September alongside the Phexxi Concierge Experience, a comprehensive patient and healthcare provider telemedicine support system.

ShowHide Related Items >><<
EVFM Evofem
$5.02 /

+0.22 (+4.58%)

EVFM Evofem
$5.02 /

+0.22 (+4.58%)

04/16/20 Roth Capital
Roth believes Evofem 'underappreciated' ahead of Phexxi PDUFA date
12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
EVFM Evofem
$5.02 /

+0.22 (+4.58%)

Hot Stocks
Saia chairman O'Dell sells nearly 10,000 common shares » 16:05
05/22/20
05/22
16:05
05/22/20
16:05
SAIA

Saia

$103.38 /

+0.37 (+0.36%)

In a regulatory filing,…

In a regulatory filing, Saia chairman Richard D. O'Dell disclosed the sale of 9,749 common shares of the company on May 21 at a price of $103.2412 per share.

ShowHide Related Items >><<
SAIA Saia
$103.38 /

+0.37 (+0.36%)

SAIA Saia
$103.38 /

+0.37 (+0.36%)

04/30/20 SunTrust
Saia price target raised to $112 from $90 at SunTrust
04/20/20 Deutsche Bank
Saia price target lowered to $90 from $101 at Deutsche Bank
04/07/20 KeyBanc
Saia downgraded to Sector Weight from Overweight at KeyBanc
03/27/20 Wolfe Research
Saia downgraded to Peer Perform from Outperform at Wolfe Research
SAIA Saia
$103.38 /

+0.37 (+0.36%)

Syndicate
Boston Properties files automatic mixed securities shelf  16:04
05/22/20
05/22
16:04
05/22/20
16:04
BXP

Boston Properties

$78.04 /

-1.84 (-2.30%)

 
ShowHide Related Items >><<
BXP Boston Properties
$78.04 /

-1.84 (-2.30%)

BXP Boston Properties
$78.04 /

-1.84 (-2.30%)

04/16/20 Jefferies
Jefferies downgrades Boston Properties to Hold, cuts price target to $94
04/16/20 Jefferies
Boston Properties downgraded to Hold from Buy at Jefferies
03/18/20 Deutsche Bank
Deutsche Bank upgrades Simon Property to Buy amid COVID-19 risks
03/10/20 Stifel
Boston Properties upgraded to Buy from Hold at Stifel
BXP Boston Properties
$78.04 /

-1.84 (-2.30%)

BXP Boston Properties
$78.04 /

-1.84 (-2.30%)

Hot Stocks
Centric Brands receives delisting notification from Nasdaq » 16:02
05/22/20
05/22
16:02
05/22/20
16:02
CTRC

Centric Brands

$0.27 /

-0.0121 (-4.29%)

Centric Brands announced…

Centric Brands announced that on May 18, 2020, it received notification from The Nasdaq Stock Market LLC, that due to the company's voluntary filing under Chapter 11 of the U.S. Bankruptcy Code on May 18, 2020, and in accordance with Nasdaq Listing Rule 5101, Nasdaq has determined that the company's common stock will be delisted from Nasdaq. This expected determination is primarily based on the Filing and associated public interest concerns raised by it. In addition, the company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2019, and was not compliant with Listing Rule 5250(c)(1).

ShowHide Related Items >><<
CTRC Centric Brands
$0.27 /

-0.0121 (-4.29%)

CTRC Centric Brands
$0.27 /

-0.0121 (-4.29%)

Hot Stocks
Tyson Foods releases results from COVID-19 testing at Temperanceville, Va plant » 15:59
05/22/20
05/22
15:59
05/22/20
15:59
TSN

Tyson Foods

$59.09 /

-0.195 (-0.33%)

Tyson Foods announced the…

Tyson Foods announced the results of facility-wide testing for COVID-19 at its Temperanceville, Virginia poultry facility. "Of the 1,282 team members and contractors who work at the facility and were tested, 257 tested positive, the majority of whom did not show any symptoms and otherwise would not have been identified. The total comprises 79 individuals who were tested by the Department of Health or when seeking care through their own health care providers and an additional 178 individuals who were tested onsite from May 5 to May 7. Team members who test positive receive paid leave and may return to work only when they have met the criteria established by both the CDC and Tyson. The Temperanceville facility is among an initial group of more than 30 production facilities in the United States where Tyson is rolling out advanced testing capabilities and enhanced care options onsite to team members in partnership with MATRIX MEDICAL, a leading medical clinical services company, and other partners. The company is prioritizing communities with a higher prevalence of COVID-19 and will assess additional needs based on significant risk factors and access to testing. As it is doing at the Temperanceville facility, Tyson will disclose test results at other plants to health and government officials, team members and stakeholders as part of its efforts to help affected communities where it operates better understand the coronavirus and the protective measures that can be taken to help prevent its spread," the company said in a post on its website. Reference Link

ShowHide Related Items >><<
TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

05/05/20
Fly Intel: Top five analyst downgrades
05/05/20 JPMorgan
Tyson Foods earnings call not as optimistic as hoped, says JPMorgan
05/05/20 BMO Capital
Tyson Foods price target lowered to $78 from $98 at BMO Capital
05/05/20 BofA
Tyson Foods downgraded to Neutral from Buy at BofA
TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

TSN Tyson Foods
$59.09 /

-0.195 (-0.33%)

Periodicals
PayPal CMO Allison Johnson leaves firm after 18-months on job, BI says » 15:48
05/22/20
05/22
15:48
05/22/20
15:48
PYPL

PayPal

$150.25 /

+2.06 (+1.39%)

, AAPL

Apple

$317.85 /

+0.93 (+0.29%)

PayPal's (PYPL) CMO…

PayPal's (PYPL) CMO Allison Johnson has left the firm after being on the job for 18 months, Business Insider's Patrick Coffee reports. Johnson had previously served as the VP of Marketing at Apple (AAPL), reporting to Steve Jobs, the report states. Reference Link

ShowHide Related Items >><<
PYPL PayPal
$150.25 /

+2.06 (+1.39%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

PYPL PayPal
$150.25 /

+2.06 (+1.39%)

05/21/20 Bernstein
PayPal e-commerce growth, new users offset competition, says Bernstein
05/18/20 Stephens
PayPal price target raised to $159 from $132 at Stephens
05/15/20
Fly Intel: Top five analyst downgrades
05/14/20 BMO Capital
BMO downgrades PayPal on shift towards credit-sensitive financials
AAPL Apple
$317.85 /

+0.93 (+0.29%)

05/18/20 Wedbush
Apple yet again caught in U.S./China Tensions, says Wedbush
05/12/20 Wedbush
Apple price target raised to $350 from $335 at Wedbush
05/07/20 Bernstein
Google payments to Apple big, predicated on advertising, says Bernstein
05/06/20 Morgan Stanley
Apple's App Store just had strongest month in 2.5 years, says Morgan Stanley
PYPL PayPal
$150.25 /

+2.06 (+1.39%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

PYPL PayPal
$150.25 /

+2.06 (+1.39%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

PYPL PayPal
$150.25 /

+2.06 (+1.39%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

PYPL PayPal
$150.25 /

+2.06 (+1.39%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

AAPL Apple
$317.85 /

+0.93 (+0.29%)

Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 » 15:42
05/22/20
05/22
15:42
05/22/20
15:42
IWM

iShares Trust Russell 2000 Index Fund

$134.42 /

+0.14 (+0.10%)

, RUT

Russell 2000 Index

$0.00 /

+ (+0.00%)

The Russell 2000 (RUT) at…

The Russell 2000 (RUT) at time of writing was set to end close to the high of the wide range in place since the end of April of this year. The 1350 level is an important one, with a boost above that level being a technical positive. For the coming week the range is 1350-1400 on the upside, with support in the range of 1340-1300. The best performing sectors were Consumer Cyclicals, Basic Materials, Energy, Industrials, Financials, and Health Care. Consumer Staples and Utilities were the least advanced in an all-green sector view.

ShowHide Related Items >><<
RUT Russell 2000 Index
$0.00 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$134.42 /

+0.14 (+0.10%)

RUT Russell 2000 Index
$0.00 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$134.42 /

+0.14 (+0.10%)

Conference/Events
Biohaven Pharmaceutical management to meet with Cantor Fitzgerald » 15:37
05/22/20
05/22
15:37
05/22/20
15:37
BHVN

Biohaven Pharmaceutical

$57.95 /

+5.76 (+11.04%)

Healthcare Analyst Duncan…

Healthcare Analyst Duncan holds a conference call with CEO Coric on May 27 at 11 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/20/20 Mizuho
Biohaven withdrawal of rimegepant NDA in line with plan, says Mizuho
05/11/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $82 from $75 at Cantor Fitzgerald
04/17/20 Cowen
Cowen initiates Biohaven Pharmaceutical with Outperform on migraine opportunity
BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

BHVN Biohaven Pharmaceutical
$57.95 /

+5.76 (+11.04%)

General news
Oil Action: Baker-Hughes rig count » 15:35
05/22/20
05/22
15:35
05/22/20
15:35

Oil Action: Baker-Hughes…

Oil Action: Baker-Hughes rig count revealed another 21 oil rigs shuttered, leaving the total at 237. This was the 10th straight week of closures. WTI crude edged a bit higher from $32.85 to near $33.45 after the report.

Technical Analysis
On The Fly: Weekly technical notes for S&P 500 » 15:33
05/22/20
05/22
15:33
05/22/20
15:33
XLI

Industrial Select Sector SPDR

$63.76 /

-0.11 (-0.17%)

, XLF

Financial Select Sector

$21.91 /

-0.085 (-0.39%)

, XLE

Energy Select Sector SPDR

$38.33 /

-0.39 (-1.01%)

, XLP

Consumer Staples Sector SPDR

$57.31 /

+0.03 (+0.05%)

, XLU

Utilities SPDR

$56.25 /

+0.39 (+0.70%)

, XLK

Technology Select Sector SPDR

$96.29 /

+0.14 (+0.15%)

, XLV

Health Care Select Sector SPDR

$99.38 /

+0.03 (+0.03%)

, SPY

SPDR S&P 500 ETF Trust

$294.84 /

+0.06 (+0.02%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

The S&P 500 (SPX) is…

The S&P 500 (SPX) is set to end the week higher, bumping up against the familiar 2950 area. This has been a very hard line of resistance that surprisingly has not been successfully challenged for long on the upside. For the coming week, the 2950-3000 area is a potential upside range test. Support is at the 2940-2910 area. Most sectors such as the Industrials (XLI), Financials (XLF), Energy (XLE), Consumer Staples (XLP), and Utilities (XLU) remain range bound. The weakest sectors are well below the midpoint of the 52-week high to low range. These are acting as drags on the index. Technology (XLK) and Health Care (XLV) are becoming range bound but at much higher levels, much closer to 52-week highs. Until that situation changes, with a broadening of the rally, the index will have difficulty advancing.

ShowHide Related Items >><<
XLF Financial Select Sector
$21.91 /

-0.085 (-0.39%)

XLE Energy Select Sector SPDR
$38.33 /

-0.39 (-1.01%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

SPX S&P 500
$0.00 /

+ (+0.00%)

XLI Industrial Select Sector SPDR
$63.76 /

-0.11 (-0.17%)

07/24/19 Gabelli
Gabelli downgrades Stanley Black & Decker to Hold on valuation
05/30/19 Deutsche Bank
Deutsche Bank makes 'Catalyst Call Buy' on UPS
XLF Financial Select Sector
$21.91 /

-0.085 (-0.39%)

XLE Energy Select Sector SPDR
$38.33 /

-0.39 (-1.01%)

XLP Consumer Staples Sector SPDR
$57.31 /

+0.03 (+0.05%)

10/23/19 Morgan Stanley
Procter & Gamble results could bode well for Walmart, says Morgan Stanley
XLU Utilities SPDR
$56.25 /

+0.39 (+0.70%)

01/15/20 Goldman Sachs
Avangrid downgraded to Sell from Neutral at Goldman Sachs
XLK Technology Select Sector SPDR
$96.29 /

+0.14 (+0.15%)

XLV Health Care Select Sector SPDR
$99.38 /

+0.03 (+0.03%)

03/18/20
Jefferies ups Health Care to Overweight, cuts Discretionary to Underweight
SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Sandler
Piper establishes 2020 S&P 500 price objective of 3,600
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

XLE Energy Select Sector SPDR
$38.33 /

-0.39 (-1.01%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

XLU Utilities SPDR
$56.25 /

+0.39 (+0.70%)

XLK Technology Select Sector SPDR
$96.29 /

+0.14 (+0.15%)

XLI Industrial Select Sector SPDR
$63.76 /

-0.11 (-0.17%)

XLF Financial Select Sector
$21.91 /

-0.085 (-0.39%)

XLE Energy Select Sector SPDR
$38.33 /

-0.39 (-1.01%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

SPX S&P 500
$0.00 /

+ (+0.00%)

XLV Health Care Select Sector SPDR
$99.38 /

+0.03 (+0.03%)

XLU Utilities SPDR
$56.25 /

+0.39 (+0.70%)

XLP Consumer Staples Sector SPDR
$57.31 /

+0.03 (+0.05%)

XLK Technology Select Sector SPDR
$96.29 /

+0.14 (+0.15%)

XLI Industrial Select Sector SPDR
$63.76 /

-0.11 (-0.17%)

XLF Financial Select Sector
$21.91 /

-0.085 (-0.39%)

XLE Energy Select Sector SPDR
$38.33 /

-0.39 (-1.01%)

SPY SPDR S&P 500 ETF Trust
$294.84 /

+0.06 (+0.02%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Options
ForeScout Technologies call volume above normal and directionally bullish » 15:25
05/22/20
05/22
15:25
05/22/20
15:25
FSCT

ForeScout

$23.19 /

+2.84 (+13.96%)

Bullish option flow…

Bullish option flow detected in ForeScout Technologies with 25,742 calls trading, 8x expected, and implied vol increasing over 5 points to 84.23%. Jun-20 25 calls and Jun-20 22.5 calls are the most active options, with total volume in those strikes near 15,000 contracts. The Put/Call Ratio is 0.17. Earnings are expected on August 5th.

ShowHide Related Items >><<
FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

02/18/20 Baird
ForeScout acquired, Baird downgrades to Neutral
02/18/20 Baird
ForeScout downgraded to Neutral from Outperform at Baird
02/07/20 Berenberg
ForeScout downgraded to Hold from Buy at Berenberg
02/07/20 Monness Crespi
ForeScout downgraded to Neutral from Buy at Monness Crespi
FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

FSCT ForeScout
$23.19 /

+2.84 (+13.96%)

Recommendations
Pinduoduo price target raised to $72 from $46.50 at CLSA » 15:22
05/22/20
05/22
15:22
05/22/20
15:22
PDD

Pinduoduo

$67.79 /

+7.75 (+12.91%)

CLSA raised the…

CLSA raised the firm's price target on Pinduoduo to $72 from $46.50 and keeps a Buy rating on the shares following the company's Q1 results. The firm said that Pinduoduo's strategic cooperation with Gome should boost its electronics and appliances offering. The firm added that GMV growth could further accelerate with growing large-ticket electronics sales, and Q2 will likely benefit from strong revenue with positive operating leverage.

ShowHide Related Items >><<
PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

05/20/20 BofA
Pinduoduo downgraded to Neutral from Buy at BofA
04/29/20 KeyBanc
Pinduoduo price target raised to $65 from $50 at KeyBanc
04/20/20 Credit Suisse
Pinduoduo upgraded to Outperform from Neutral at Credit Suisse
03/11/20 Citi
Pinduoduo downgraded to Neutral at Citi
PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

PDD Pinduoduo
$67.79 /

+7.75 (+12.91%)

General news
U.S. Commerce Department adds 9 Chinese entities to entity list, Bloomberg says » 15:21
05/22/20
05/22
15:21
05/22/20
15:21
SPY

SPDR S&P 500 ETF Trust

$295.20 /

+0.42 (+0.14%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

Human rights abuses in…

Human rights abuses in Xinjiang were cited for the move, Bloomberg noted.

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Sandler
Piper establishes 2020 S&P 500 price objective of 3,600
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.20 /

+0.42 (+0.14%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Technical Analysis
NASDAQ market internals summary » 15:17
05/22/20
05/22
15:17
05/22/20
15:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Volume is above average for this time of day. Breadth is bullish across the board. Advancing Issues: 1585 / Declining Issues: 1622 -- for a ratio of 1 to 1. Advancing Volume: 1,788,022,000 / Declining Volume: 1,089,767,000 -- for a ratio of 1.6 to 1. New 52-Week Highs: 70 / New 52-Week Lows: 9.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 15:16
05/22/20
05/22
15:16
05/22/20
15:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is average for…

Volume is average for this time of day. Breadth is mixed with issues bullish, volume is bearish and new highs to new lows are bullish (positive divergence). Advancing Issues: 1467 / Declining Issues: 1451 -- for a ratio of 1 to 1. Advancing Volume: 1,109,691,000 / Declining Volume: 1,701,467,000 -- for a ratio of 0.7 to 1. New 52-Week Highs: 31 / New 52-Week Lows: 11.

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Recommendations
Atara multiple sclerosis data looks 'awesome' at first glance, says Mizuho » 15:14
05/22/20
05/22
15:14
05/22/20
15:14
ATRA

Atara Biotherapeutics

$16.49 /

+1.57 (+10.52%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed noted that the full Atara Biotherapeutics poster for its presentation at a medical conference of progressive multiple sclerosis study data has been released, calling it "awesome data on first glance" as the details are still being reviewed. In progressive multiple sclerosis patients, where there is an unmet need, improving on disability from baseline "is a big deal," added Syed. The analyst has a Buy rating on Atara shares.

ShowHide Related Items >><<
ATRA Atara Biotherapeutics
$16.49 /

+1.57 (+10.52%)

ATRA Atara Biotherapeutics
$16.49 /

+1.57 (+10.52%)

04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
ATRA Atara Biotherapeutics
$16.49 /

+1.57 (+10.52%)

General news
Treasury Action: Treasuries rallied ahead of the long weekend » 15:10
05/22/20
05/22
15:10
05/22/20
15:10

Treasury Action:…

Treasury Action: Treasuries rallied ahead of the long weekend as rising geopolitical tensions between the U.S. and China, and Hong Kong and China supported. The wi 2-year closed unchanged at 0.175%, while the 10-year was 1.3 bps lower at 0.659%, the 20-year was down 3 bps to 1.122%, and the 30-year was off 1.6 bps to 1.37%. All have edged up from Asia session lows, however, as stocks bounce. There's not much room on the downside for shorted dated rates to slide (especially if the Fed won't be going to negative rates), hence pushing a haven bid down the curve. The strong 20-year auction results also continued to reflect demand for positive yield, especially with a lack of inflation pressures over the foreseeable future, and as the FOMC discussed capping rates. The long end should also benefit from month-end flows with a larger than usual duration extension for June 1 as a result of the re-introduction of the 20-year. Barclays estimates a 0.14 year Treasury index, versus 0.12 year from June 2019, and with 12-month and 10-year averages of 0.11 years.

Hot Stocks
RBF Capital proposes to acquire Asta Funding for $13 per share in cash » 14:58
05/22/20
05/22
14:58
05/22/20
14:58
ASFI

Asta Funding

$11.40 /

+0.04 (+0.35%)

In a regulatory filing,…

In a regulatory filing, RBF Capital disclosed that on May 22 the firm sent a letter to the board of directors of Asta Funding, proposing to acquire all of the outstanding shares of the company not currently held by RBF for a price of $13.00 per share in cash, representing a 13% premium to the Stern Group's proposed purchase price. RBF is a family office managed by Richard Fullerton and intends to finance the proposed acquisition with internal cash, the filing stated. RBF is "prepared to immediately negotiate a confidentiality agreement, commence due diligence and begin negotiation of definitive documentation for a transaction," the filing added. On April 8, Asta Funding announced that it has entered into a definitive merger agreement under which the Stern Group, comprised of Gary Stern, Ricky Stern and certain related parties, will acquire the outstanding publicly held shares of common stock of Asta through the merger of Asta with a wholly-owned subsidiary of Asta Finance Acquisition, with Asta surviving as a wholly-owned subsidiary of the parent. Each share of outstanding common stock will be purchased for $11.47 in cash.

ShowHide Related Items >><<
ASFI Asta Funding
$11.40 /

+0.04 (+0.35%)

Recommendations
Baird 'opportunistic buyers' of Alibaba shares after earnings » 14:50
05/22/20
05/22
14:50
05/22/20
14:50
BABA

Alibaba

$199.85 /

-12.15 (-5.73%)

Baird analyst Colin…

Baird analyst Colin Sebastian said he remains an "opportunistic buyer" of Alibaba shares after the company's Q4 results beat consensus and the high-end of his estimates. Alibaba is already generating roughly one-sixth of retail volume in China and its digital transformation opportunity remains "very large," contends Sebastian. While the recent Senate proposal to de-list foreign controlled companies may remain a slight near-term overhang, he thinks it is unlikely to create a "credible risk" to Alibaba and would be a buyer on any related pullbacks, the analyst added. Sebastian maintains an Outperform rating on the stock with a $230 price target.

ShowHide Related Items >><<
BABA Alibaba
$199.85 /

-12.15 (-5.73%)

BABA Alibaba
$199.85 /

-12.15 (-5.73%)

05/22/20 Goldman Sachs
Goldman Sachs keeps Buy rating on Alibaba after better than expected Q4
04/09/20 Morgan Stanley
Alibaba 'core of core' revenue recovery outlook improved, says Morgan Stanley
03/23/20 Oppenheimer
Tencent, Baidu, Alibaba attractive at current levels, says Oppenheimer
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
BABA Alibaba
$199.85 /

-12.15 (-5.73%)

BABA Alibaba
$199.85 /

-12.15 (-5.73%)

BABA Alibaba
$199.85 /

-12.15 (-5.73%)

BABA Alibaba
$199.85 /

-12.15 (-5.73%)

Periodicals
Trump says CDC to issue guidelines calling worship places essential, WSJ says » 14:44
05/22/20
05/22
14:44
05/22/20
14:44
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$295.05 /

+0.265 (+0.09%)

U.S. President Donald…

U.S. President Donald Trump said that the CDC would be issuing new guidelines that designate places of worship as essential, noting that he would overrule any state's governor who disagreed with the guidelines, the Wall Street Journal's Gordon Lubold reports. The president said that some governors have determined that abortion clinics and liquor stores are seential but opted against putting churches and other places of worship in that category, Lubold notes. "So I'm correcting this injustice and calling houses of worship essential," Trump said during a previously unscheduled visit to the White House briefing room. "I call upon the governors to allow our churches or places of worship to open," he said. "Now, if there's any question, they're gonna have to call me but they're not going to be successful in that call." Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$295.05 /

+0.265 (+0.09%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Sandler
Piper establishes 2020 S&P 500 price objective of 3,600
SPY SPDR S&P 500 ETF Trust
$295.05 /

+0.265 (+0.09%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.05 /

+0.265 (+0.09%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.05 /

+0.265 (+0.09%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Hot Stocks
Asta Funding trading halted, news dissemination  14:41
05/22/20
05/22
14:41
05/22/20
14:41
ASFI

Asta Funding

$11.40 /

+0.04 (+0.35%)

 
ShowHide Related Items >><<
ASFI Asta Funding
$11.40 /

+0.04 (+0.35%)

Recommendations
Splunk price target raised to $200 from $155 at JMP Securities » 14:41
05/22/20
05/22
14:41
05/22/20
14:41
SPLK

Splunk

$184.19 /

+20.92 (+12.81%)

JMP Securities analyst…

JMP Securities analyst Erik Suppiger raised the firm's price target on Splunk to $200 from $155 and keeps an Outperform rating on the shares after the company reported Q1 results. Its 40% cloud mix was noted as the company's highest ever cloud mix and the strength in cloud adoption implies the company is "executing better in the cloud than competitors have suggested," Suppiger said. In the second quarter that Splunk offered its new pricing model an increasing number of customers are adopting the infrastructure based pricing metric, the analyst also said. The company also expressed confidence in its mid-40% ARR target growth rate, Suppiger noted.

ShowHide Related Items >><<
SPLK Splunk
$184.19 /

+20.92 (+12.81%)

SPLK Splunk
$184.19 /

+20.92 (+12.81%)

05/22/20 JPMorgan
Splunk price target raised to $190 from $174 at JPMorgan
05/22/20 Raymond James
Splunk price target raised to $185 from $140 at Raymond James
05/22/20 Oppenheimer
Splunk price target raised to $190 from $145 at Oppenheimer
05/22/20 BMO Capital
Splunk price target raised to $190 from $177 at BMO Capital
SPLK Splunk
$184.19 /

+20.92 (+12.81%)

SPLK Splunk
$184.19 /

+20.92 (+12.81%)

SPLK Splunk
$184.19 /

+20.92 (+12.81%)

Options
Canopy Growth call volume above normal and directionally bullish » 14:25
05/22/20
05/22
14:25
05/22/20
14:25
CGC

Canopy Growth

$19.15 /

+0.91 (+4.99%)

Bullish option flow…

Bullish option flow detected in Canopy Growth with 65,462 calls trading, 3x expected, and implied vol increasing almost 8 points to 95.21%. Jun-20 10 puts and Jun-20 20 calls are the most active options, with total volume in those strikes near 35,100 contracts. The Put/Call Ratio is 0.67. Earnings are expected on May 29th.

ShowHide Related Items >><<
CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

05/22/20 BofA
Canopy Growth resumed with a Buy at BofA
05/14/20 Cantor Fitzgerald
Canopy Growth price target lowered to C$25 from C$27 at Cantor Fitzgerald
04/16/20
Fly Intel: Top five analyst upgrades
04/16/20 Jefferies
Canopy Growth upgraded to Hold following pullback at Jefferies
CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

CGC Canopy Growth
$19.15 /

+0.91 (+4.99%)

Hot Stocks
Atara jumps after data released on multiple sclerosis study » 14:24
05/22/20
05/22
14:24
05/22/20
14:24
ATRA

Atara Biotherapeutics

$16.79 /

+1.87 (+12.53%)

Data being presented at…

Data being presented at the virtual European Academy of Neurology meeting next week in a late-breaking abstract related to ATA188, an allogeneic cell therapy being developed by Atara Biotherapeutics, has been released and shows one Expanded Disability Status Scale, or EDSS, improvement in the five million cell cohort, and none in subjects given 10 million cells, according to Jacob Plieth of Evaluate Vantage. In the high-dose 40 million cells cohort two of six subjects are showing EDSS improvement, according to Plieth, who cautions that "this is only at six months, and has yet to be confirmed with a 12-month reading." In afternoon trading, shares of Atara are off their earlier highs but remain up $2.47, or 16.5%, at $17.40 as of 2:22 pm ET. Reference Link

ShowHide Related Items >><<
ATRA Atara Biotherapeutics
$16.79 /

+1.87 (+12.53%)

ATRA Atara Biotherapeutics
$16.79 /

+1.87 (+12.53%)

04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to Neutral from Overweight at JPMorgan
ATRA Atara Biotherapeutics
$16.79 /

+1.87 (+12.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.